Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 498

1.

Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V.

Arch Intern Med. 2010 Jun 14;170(11):977-85. doi: 10.1001/archinternmed.2010.134.

PMID:
20548011
2.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
3.

Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.

Ciotti M, Sesti F, Paba P, Benedetto A, Patrizi L, Criscuolo A, Piccione E, Branca M, Syrjänen K, Favalli C.

Eur J Gynaecol Oncol. 2004;25(5):577-84.

PMID:
15493169
4.

Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".

Sawaya GF.

Arch Intern Med. 2010 Jun 14;170(11):985-6. doi: 10.1001/archinternmed.2010.133. No abstract available.

PMID:
20548012
5.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

PMID:
19141778
6.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

7.

Chapter 13: Primary screening of cervical cancer with human papillomavirus tests.

Franco EL.

J Natl Cancer Inst Monogr. 2003;(31):89-96. Review.

PMID:
12807951
8.

Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States.

Roland KB, Soman A, Benard VB, Saraiya M.

Am J Obstet Gynecol. 2011 Nov;205(5):447.e1-8. doi: 10.1016/j.ajog.2011.06.001. Epub 2011 Jun 12.

PMID:
21840492
9.

Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.

Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K.

J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061.

PMID:
18573778
10.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
11.

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensee M, Suhr CJ, Weinstock H.

Ann Intern Med. 2008 Apr 1;148(7):493-500.

PMID:
18378945
12.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
13.

Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.

Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris DG, Lörincz A, Hernández P, Salmerón J; Morelos HPV Study Collaborators.

Salud Publica Mex. 2002 Jul-Aug;44(4):335-44.

PMID:
12216521
15.

Comparative analysis of a liquid-based Pap test and concurrent HPV DNA assay of residual samples. A study of 608 cases.

Hong IS, Marshalleck J, Williams RH, Gaiter TE, Mielzynska-Lohnas I, Kim K.

Acta Cytol. 2002 Sep-Oct;46(5):828-34.

PMID:
12365215
16.

Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.

Cox JT.

Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S15-25. Review.

PMID:
16729900
17.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group.

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

PMID:
16757701
18.

Impact of pap test compliance and cervical cancer screening intervals on human papillomavirus vaccine acceptance.

Ferris DG, Waller J, Dickinson A, McCracken C, Goebel A.

J Low Genit Tract Dis. 2012 Jan;16(1):39-44. doi: 10.1097/LGT.0b013e31822e8e25.

PMID:
22126831
20.

Supplemental Content

Support Center